dianicline
Dianicline (SSR-591,813) is a drug developed by Sanofi-Aventis which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It is being developed as a medication for the treatment of nicotine dependence to assist in smoking cessation. Dianicline is very similar to the already marketed drug varenicline and it is unclear what advantages it will have over the older drug, although it may have an improved side effect profile. It has been through human trials up to Phase II, although results have not yet been reported. Drug development has been discontinued after reporting of unfavourable results during Phase III trials. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Jun 1, 2006 (NCT00356967)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Muscle-type nicotinic acetylcholine receptorPARTIAL AGONIST
Muscle-type nicotinic acetylcholine receptor partial agonist
- Neuronal acetylcholine receptor; alpha4/beta2PARTIAL AGONIST
Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
Chemistry & pharmacology
SMILES
c1cnc2c(c1)O[C@H]1CCN3CC[C@@]1(C2)C3- Mol. weight
- 216.28 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDianicline ↗
- ChEMBLCHEMBL187927 ↗
Also known as
- 5a,6,9,10-tetrahydro-7h,11h-8,10a-methanopyrido(2',3'-5,6)pyrano(2,3-d)azepine
- dianicline
- dianicline
- dianicline
- dianicline
- dianicline
- ssr591813
- ssr 591813
- ssr-591813
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00387946 | Phase 3 | Sep 1, 2006 | Sanofi |
| NCT00356967 | Phase 3 | Jun 1, 2006 | Sanofi |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 2 | 2 | 1 | 2006 |